Philip Scheltens (Edmond Sadaka/Sipa via AP Images)

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

Big Phar­ma has re­treat­ed from neu­ro­science over the past sev­er­al years, aban­don­ing or trim­ming back pro­grams af­ter fac­ing set­backs in dif­fi­cult-to-treat brain dis­or­ders. And now, René Kui­jten says de­men­tia op­por­tu­ni­ties re­main “large­ly un­fund­ed.”

That’s where Eu­ro­pean life sci­ences in­vestor LSP comes in.

Kui­jten, LSP’s man­ag­ing part­ner, found­ed the LSP De­men­tia Fund to sup­port biotechs search­ing for new treat­ments for neu­rode­gen­er­a­tive dis­eases. In the last few months, he’s pulled to­geth­er €50 mil­lion ($60.5 mil­lion), and he hopes to even­tu­al­ly raise at least €150 mil­lion ($181.7 mil­lion).

René Kui­jten LSP

“In the past two decades, ven­ture cap­i­tal has proven to play an es­sen­tial role in ad­vanc­ing biotech com­pa­nies, but de­men­tia op­por­tu­ni­ties re­mained large­ly un­fund­ed,” Kui­jten, who de­clined an in­ter­view, said in a state­ment.

The fund will be man­aged by Philip Schel­tens, pro­fes­sor of cog­ni­tive neu­rol­o­gy at Am­s­ter­dam Uni­ver­si­ty Med­ical Cen­ters and founder of Alzheimer Cen­ter Am­s­ter­dam. It’ll fo­cus on all stages of de­men­tia drug and medtech de­vel­op­ment for dis­eases, like Alzheimer’s, that cause de­men­tia.

“I am ex­cit­ed to make this move in my ca­reer to re­alise treat­ment op­tions for pa­tients, build­ing on and com­bin­ing it with the work I was able to do at the Alzheimer Cen­ter Am­s­ter­dam,” Schel­tens said in a state­ment.

In May 2019, BIO re­leased a re­port on the state of Alzheimer’s re­search, which called ven­ture in­vest­ment in the space “in­suf­fi­cient.” At the time, ven­ture fund­ing of US com­pa­nies with lead pro­grams in Alzheimer’s dis­ease was 16 times be­low on­col­o­gy fund­ing, BIO re­port­ed.

For­mer BIO pres­i­dent and CEO Jim Green­wood seemed op­ti­mistic about the many clin­i­cal-stage pro­grams in the works to tack­le the de­bil­i­tat­ing dis­ease. But the “bad news,” he wrote, is that “while these pro­grams hold re­al promise, the R&D chal­lenges with this dis­ease are enor­mous and the lev­el of in­vest­ment and in­no­va­tion is not where our na­tion needs it to be to ad­dress this ex­plod­ing pub­lic health cri­sis.”

With over 50 mil­lion pa­tients suf­fer­ing world­wide from de­men­tia, LSP called the dis­ease the “great­est health­care chal­lenge of our time.”

“To­geth­er with Philip and his net­work, we now have a tru­ly unique ex­per­tise in-house to iden­ti­fy and de­vel­op break­through ideas in the de­men­tia field, ul­ti­mate­ly lead­ing to so­lu­tions for pa­tients suf­fer­ing from this ter­ri­ble dis­ease,” Kui­jten said.

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Yanay Ofran (L) and Anat Binur (Ukko)

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

Little capsules of peanut powder drove Nestlé’s $2.6 billion buyout of Aimmune. Now, with $40 million in new funding, a fledgling biotech is promising to bring a more sophisticated version of that protein therapy that can go much, much further.

Ukko’s goal is two-pronged — with the initial products spanning therapeutic and food — but it’s grounded in the same protein engineering platform, co-founder and CEO Anat Binur told Endpoints News.

As tar­get­ed ther­a­pies get ever more pre­cise, Deer­field un­veils $50M bet on an Har­vard pro­fes­sor's chem­istry in­sights

Behind the seemingly simple concept of targeted cancer therapies is the drug developer’s headache that the target is always changing. Each generation of kinase inhibitors may be ostensibly hitting the same oncogene, but in addition to blocking the wildtype oncogene, they must now also address the mutations that have developed along the way, spurring resistance to current drugs.

The more those target kinases evolve, too, the more they could resemble off-target kinases you don’t want to bind. So each iteration requires more selectivity — sometimes down to differences of a few atoms.

Vincent Sandanayaka (file photo)

UP­DAT­ED: Ex-MD An­der­son chief De­Pin­ho is help­ing launch an­oth­er biotech — and he's stick­ing with fa­mil­iar ground

Years after co-founding SINE-focused Karyopharm and stirring up controversy at MD Anderson, Ronald DePinho is helping uncloak a new biotech targeting solute carrier transporter proteins — and Karyopharm’s former head of chemistry is leading the charge.

Nirogy Therapeutics emerged from stealth mode on Tuesday with a $16.5 million Series A round and plans to hit the clinic by 2022. The financing should be enough to carry the startup’s lead program, a small molecule lactate transport inhibitor, through Phase I, CEO Vincent Sandanayaka said.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.